Natixis Advisors, L.P. Acadia Pharmaceuticals Inc Transaction History
Natixis Advisors, L.P.
- $46 Billion
- Q2 2024
A detailed history of Natixis Advisors, L.P. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 25,527 shares of ACAD stock, worth $377,544. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,527
Previous 17,830
43.17%
Holding current value
$377,544
Previous $330,000
25.76%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ACAD
# of Institutions
288Shares Held
161MCall Options Held
723KPut Options Held
257K-
Baker Bros. Advisors LP New York, NY42.9MShares$634 Million9.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.7MShares$203 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$203 Million3.72% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$85.8 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.39B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...